ArticleFrontiers in oncology2026
Sex-based survival disparities in patients with stage I-III non-small cell lung cancer vary by treatment modality.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Female sex is a well-established prognostic factor in non-small cell lung cancer (NSCLC). Most prior studies are restricted to single-treatment cohorts and seldom include best supportive care (BSC), limiting the evaluation of sex-based median overall survival across the full treatment spectrum, BSC included. Methods: We conducted a retrospective study of patients diagnosed with clinical stage I-III NSCLC treated with curative intent (surgery, radiotherapy, or chemoradiation) or primary BSC. Survival rate was analyzed using log-rank tests and multivariable Cox regression to adjust for confounding prognostic factors. Results: In the total curative treatment cohort (n=1634), median overall survival (mOS) was 74.5 and 44.6 months in female and male patients, respectively [hazard ratio (HR) 0.60, P<0.001]. However, in the BSC cohort (n=234), mOS was similar between female (5.9 months) and male (5.8 months) patients (HR 0.93, P = 0.60). After stratification, mOS was not reached (females) versus 66.4 months (males) after surgery, (HR 0.58, P<0.001); 46.2 months (females) versus 33.0 months (males) after radiotherapy (HR 0.64, P<0.001); and 39.3 months (females) versus 26.9 months (males) after chemoradiation (HR 0.63, P<0.001). After multivariable adjustment, female survival benefit remained significant after curative-intent treatment overall (HR 0.72, P<0.001), surgery (HR 0.69, P = 0.003), and chemoradiation (HR 0.72, P = 0.02), but not after radiotherapy (HR 0.80, P = 0.12). Conclusions: Female survival advantage in stage I-III NSCLC is treatment-dependent and absent in the BSC cohort. Prospective studies with more detailed clinical, biological, and sociodemographic data are needed to determine whether sex independently affects survival or reflects other prognostic factors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.